Xg Locus : Failure to detect Inactivation in Females with Chronic Myelocytic Leukaemia

Nature ◽  
1970 ◽  
Vol 226 (5243) ◽  
pp. 367-368 ◽  
Author(s):  
P. J. FIALKOW ◽  
R. LISKER ◽  
ELOISE R. GIBLETT ◽  
C. ZAVALA
Keyword(s):  
Chronic Myelocytic Leukaemia ◽  
Myelocytic Leukaemia

Cytogenetic Studies During Remission of Blastic Crisis in a Patient with Chronic Myelocytic Leukaemia

2009 ◽  
Vol 10 (2) ◽  
pp. 130-135 ◽  
Author(s):  
C. H. Srodes ◽  
E. F. Hyde ◽  
S. F. Pan ◽  
P. A. Chervenick ◽  
D. R. Boggs
Keyword(s):  
Blastic Crisis ◽  
Cytogenetic Studies ◽  
Chronic Myelocytic Leukaemia ◽  
Myelocytic Leukaemia

Decreased L‐selectin expression in CD34‐positive cells from patients with chronic myelocytic leukaemia

1996 ◽  
Vol 93 (2) ◽  
pp. 367-374 ◽  
Author(s):  
KUNIKO KAWAISHI ◽  
AKIRO KIMURA ◽  
OSAMU KATOH ◽  
AYAKO SASAKI ◽  
NOBUO OGUMA ◽  
...  
Keyword(s):  
Chronic Myelocytic Leukaemia ◽  
Myelocytic Leukaemia

scholarly journals Shift from Rh-positive to Rh-negative phenotype caused by a somatic mutation within the RHD gene in a patient with chronic myelocytic leukaemia

1998 ◽  
Vol 102 (5) ◽  
pp. 1263-1270 ◽  
Author(s):  
Baya CHÉrif-Zahar ◽  
Viviane Bony ◽  
Rudi Steffensen ◽  
Pierre Gane ◽  
Virginie Raynal ◽  
...  
Keyword(s):  
Somatic Mutation ◽  
Chronic Myelocytic Leukaemia ◽  
Myelocytic Leukaemia ◽  
Negative Phenotype

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

Nature ◽  
1982 ◽  
Vol 300 (5894) ◽  
pp. 765-767 ◽  
Author(s):  
Annelies de Klein ◽  
Ad Geurts van Kessel ◽  
Gerard Grosveld ◽  
Claus R. Bartram ◽  
Anne Hagemeijer ◽  
...  
Keyword(s):  
Philadelphia Chromosome ◽  
Cellular Oncogene ◽  
Chronic Myelocytic Leukaemia ◽  
Myelocytic Leukaemia

scholarly journals CYP1A1 and CYP2D6 Polymorphisms and Susceptibility to Chronic Myelocytic Leukaemia

2020 ◽  
Vol 20 (9) ◽  
pp. 675-680
Author(s):  
Hadeil M.E. Idris ◽  
Hiba B. Khalil ◽  
Jeremy Mills ◽  
Abozer Y. Elderdery
Keyword(s):  
Control Group ◽  
P Value ◽  
Metabolizing Enzymes ◽  
Pcr Rflp ◽  
Carcinogenic Substances ◽  
Study Population ◽  
Chronic Myelocytic Leukaemia ◽  
Myelocytic Leukaemia ◽  
Blood Specimens ◽  
A Prospective Study

Background: CYP1A1 and CYP2D6 are both xenobiotic metabolizing enzymes belonging to the CYP450 enzyme family. Polymorphisms in these genes vary between individuals, resulting in dissimilar patterns of susceptibility to the effects of carcinogenic substances and drugs. Objective: In a prospective study, the influence of CYP1A1*2C and CYP2D6*4 gene polymorphisms on the susceptibility to chronic myelocytic leukaemia (CML) were investigated. Methods: Prevalence of CYP1A1*2C and CYP2D6*4 was detected in blood specimens from three hundred participants - two hundred patients and a hundred healthy individuals as a control group, using PCR-RFLP. Results: CYP1A1 Ile/Val and Val/Val genotype frequency in our study population was 82% & 15% in CML patients and 55% & 8% in controls, respectively. This suggests that carriers had an elevated risk (OR=18.38, 95% CI=7.364-45.913, p value; =0.000 and OR=23.125,95 % CI=7.228-73.980, p value=0.000, respectively). Individuals carrying the CYP2D6 heterozygous genotype (IM) were notably fewer in number within the CML group at 43.5%, as opposed to 93% of the controls. This suggests that the IM genotype may have a prophylactic function in lowering CML risk (OR=0.036, 95% CI=0.005-0.271, p value =0.001). In spite of the distribution of the homozygous mutant (PM) genotype being higher in cases with CML (87% as opposed to 6% in the control), this difference was deemed non-significant (OR=0.558, 95% CI=0.064-4.845, p value =0.597). Conclusion: These findings indicate that polymorphic CYP1A1 and CYP2D6 genes affect the susceptibility to CML.

Azathioprine in Myeloproliferative and Autoimmune Disorders

1968 ◽  
Vol 17 (1) ◽  
pp. 258-269
Author(s):  
D. Taglioretti ◽  
A. Giangrande
Keyword(s):  
Haemolytic Anaemia ◽  
Acute Leukaemia ◽  
Clinical Results ◽  
Similar Group ◽  
Systemic Lupus ◽  
Results Of Treatment ◽  
Chronic Myelocytic Leukaemia ◽  
Myelocytic Leukaemia ◽  
Haematological Remission ◽  
Autoimmune Pathogenesis

SummaryThe report presents the clinical results of treatment with Azathioprine 6 [(methyl-4-nitro-5-imidazolyl) thio] purine, in patients with acute leukaemia, the acute relapsing phase of chronic myelocytic leukaemia and in a group of patients affected by illness which have probably an autoimmune pathogenesis.Favorable results were obtained in the group of patients suffering from acute leukaemia with a percentage of clinical and/or haematological remission of 57%.A comparative analysis of the length of survival in these patients compared to that of a similar group of patients treated with 6-mercaptopurine is also reported.A fair response was also obtained in the group of patients in the acute relapsing phase of C.M.L.In the group of patients affected by diseases probably due to an immune pathogenesis, a favorable response was obtained in 2 cases of systemic lupus erithematosus with haemolytic anaemia and 1 case of acquired autoimmune haemolytic anaemia.

Preliminary experience with imatinib mesylate therapy of Ph+ chronic myelocytic leukaemia in Ile-Ife Nigeria

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 3216-3216
Author(s):  
M. A. Durosinmi ◽  
J. O. Faluyi ◽  
C. C. Okany ◽  
S. A. Akanmu ◽  
I. A. Adediran ◽  
...  
Keyword(s):  
Imatinib Mesylate ◽  
Chronic Myelocytic Leukaemia ◽  
Myelocytic Leukaemia
Sign in / Sign up

Export Citation Format

Share Document